NVNO - enVVeno: The Road To Approval Seems Open From Here On
2024-03-06 17:59:20 ET
Summary
- enVVeno Medical Corporation has released remarkably positive topline data from its pivotal trial for the VenoValve.
- The path to file for approval in Q4 2024 seems open.
- The VenoValve targets a significant market of 2.5 million patients in the US alone, with potential pricing between $20,000 and $25,000 per device.
- enVVeno is well-funded and has strong financial backing, making it a compelling investment opportunity with significant upside potential.
Thesis
enVVeno Medical Corporation ( NVNO ) is an undercovered microcap company focusing on treatments for vascular disease Chronic Venous Insufficiency.
enVVeno has just released positive topline data of its pivotal trial in 75 patients with chronic venous insufficiency, treated with the VenoValve. Well beyond expectations, 97% of the patients showed clinical improvement at six months, and 74% of them showed a clinically meaningful benefit at that time on the relevant rating scale. The average improvement on that same scale was more than 2.5 times the amount necessary to show clinical benefit.
The company is awaiting full twelve-month safety data, and should then be on track to file for FDA Approval in Q4 2024....
enVVeno: The Road To Approval Seems Open From Here On